Yunnan's self-produced plasma-derived medicinal products make debut at China-South Asia Exposition
km.gov.cn |
Updated: 2022-11-21 19:08
Share
Share - WeChat
The COMOS-standard digital plant has been designed and built in accordance with both European and Chinese GMP norms, and has been integrated with smart manufacturing concept and information technology in a drive to achieve whole-process automation, precise and standard control as well as management.
With the technical support of Beijing Tiantan Biological Products Co Ltd -- a unit of Sinopharm subsidiary China National Biotec Group (CNBG) and a parent company of Sinopharm Shanghai Plasma-derived Biotherapies and Sinopharm Kunming Plasma-Derived Biotherapies -- the project went into trial production with the debagging its first bag of plasma on Oct 17.
